$CRME at support off 10 & 20 day $3.15 Website
Post# of 63818
(Total Views: 206)
Posted On: 04/14/2017 3:24:19 PM
$CRME at support
off 10 & 20 day $3.15
Website
80% x 100% Strong Buy
40-F 3/29/17
Low float
Shares Outstanding 31.88M
Float 23.14M
% Held by Insiders 35.64%
% Held by Institutions 19.00%
Shares Short 3 83.32k
Short Ratio 1.27
Short % of Float 1.67%
Shares Short (prior month) 114.83k
Stock technical analysis
Cardiome Pharma Corp., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of patients suffering from heart diseases. It offers BRINAVESS (vernakalant (IV)) for the conversion of recent onset atrial fibrillation to sinus rhythm in adults; and AGGRASTAT, a reversible GP IIb/IIIa inhibitor for use in acute coronary syndrome patients. The company also provides ESMOCARD and ESMOCARD LYO short-acting beta-blockers used to control rapid heart rate; XYDALBA, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections; and TREVYENT for the treatment of pulmonary arterial hypertension. It has operations in Canada, the United States, Europe, and internationally. The company was formerly known as Nortran Pharmaceuticals Inc. and changed its name to Cardiome Pharma Corp. in June 2001. Cardiome Pharma Corp. was founded in 1986 and is headquartered in Vancouver, Canada.
off 10 & 20 day $3.15
Website
80% x 100% Strong Buy
40-F 3/29/17
Low float
Shares Outstanding 31.88M
Float 23.14M
% Held by Insiders 35.64%
% Held by Institutions 19.00%
Shares Short 3 83.32k
Short Ratio 1.27
Short % of Float 1.67%
Shares Short (prior month) 114.83k
Stock technical analysis
Cardiome Pharma Corp., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of patients suffering from heart diseases. It offers BRINAVESS (vernakalant (IV)) for the conversion of recent onset atrial fibrillation to sinus rhythm in adults; and AGGRASTAT, a reversible GP IIb/IIIa inhibitor for use in acute coronary syndrome patients. The company also provides ESMOCARD and ESMOCARD LYO short-acting beta-blockers used to control rapid heart rate; XYDALBA, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections; and TREVYENT for the treatment of pulmonary arterial hypertension. It has operations in Canada, the United States, Europe, and internationally. The company was formerly known as Nortran Pharmaceuticals Inc. and changed its name to Cardiome Pharma Corp. in June 2001. Cardiome Pharma Corp. was founded in 1986 and is headquartered in Vancouver, Canada.
(0)
(0)